Articles
Article Tools
 View Full Text |
 Abstract |
 Article as PDF |
 Print this Article |
 Pubmed |
 PMC |
 PubReader |
 Export to Citation |
 Email Alerts |
 Open Access |
Supplementary
Share this article on :
Stats or Metrics
Article
Original Article
Exp Neurobiol 2019; 28(6): 720-726
Published online December 31, 2019
https://doi.org/10.5607/en.2019.28.6.720
© The Korean Society for Brain and Neural Sciences
B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis
Young Gi Min1, Canaria Park2, Young-Nam Kwon1,3, Je-Young Shin1, Jung-Joon Sung1,2 and Yoon-Ho Hong2,3*
1Department of Neurology, Seoul National University Hospital, Seoul 03080, 2Seoul National University College of Medicine and Neuroscience Research Institute, Seoul National University Medical Research Council, Seoul 03080, 3Department of Neurology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, Korea
Correspondence to: *To whom correspondence should be addressed.
TEL: 82-2-870-2474, FAX: 82-2-831-2826
e-mail: nrhong@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorders mediated by various autoantibodies. Although most patients with MG require chronic immunosuppressive treatment to control disease activity, appropriate surveillance biomarkers that monitor disease activity or potential toxicity of immunosuppressants are yet to be developed. Herein, we investigated quantitative distribution of peripheral blood B cell subsets and transcriptional profiles of memory B cells (CD19+ CD27+) in several subgroups of MG patients classified according to the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification. This study suggests potential immunologic B-cell markers that may guide treatment decision in future clinical settings.
Graphical Abstract
Keywords: Myasthenia gravis, B-lymphocytes, Biomarkers, Flow cytometry, Transcriptome
